Clinical outcomes of patients with major depressive disorder treated with either duloxetine, escitalopram, fluoxetine, paroxetine, or sertraline

about

Clinical outcomes of patients with major depressive disorder treated with either duloxetine, escitalopram, fluoxetine, paroxetine, or sertraline

Item

http://www.wikidata.org/entity/Q57491808

description

im Jahr 2018 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована у 2018

@uk

name

Clinical outcomes of patients ...... ine, paroxetine, or sertraline

@en

Clinical outcomes of patients ...... ine, paroxetine, or sertraline

@nl

type

Item

label

Clinical outcomes of patients ...... ine, paroxetine, or sertraline

@en

Clinical outcomes of patients ...... ine, paroxetine, or sertraline

@nl

prefLabel

Clinical outcomes of patients ...... ine, paroxetine, or sertraline

@en

Clinical outcomes of patients ...... ine, paroxetine, or sertraline

@nl

P1476

Clinical outcomes of patients ...... ine, paroxetine, or sertraline

@en

P2093

Jia Huang

http://www.w3.org/2001/XMLSchema#string

Jun Chen

http://www.w3.org/2001/XMLSchema#string

Li Yue

http://www.w3.org/2001/XMLSchema#string

Maria Victoria Moneta

http://www.w3.org/2001/XMLSchema#string

Yanlei Zhang

http://www.w3.org/2001/XMLSchema#string

Yiru Fang

http://www.w3.org/2001/XMLSchema#string

Yun Wang

http://www.w3.org/2001/XMLSchema#string

Zheng Yuan

http://www.w3.org/2001/XMLSchema#string

P2860

Duloxetine versus other anti-depressive agents for depression

Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010

Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study

Physical symptoms in primary care. Predictors of psychiatric disorders and functional impairment

Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents

The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R)

Evaluation of the effect of duloxetine treatment on functioning as measured by the Sheehan disability scale: pooled analysis of data from six randomized, double-blind, placebo-controlled clinical studies.

Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors.

The importance of functional impairment to mental health outcomes: a case for reassessing our goals in depression treatment research.

The epidemiology of depression across cultures

P304

2473-2484

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/NDT.S159800

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P50

Josep Maria Haro

Diego Novick

P577

2018-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30310285

http://www.w3.org/2001/XMLSchema#string

P932

6165742

http://www.w3.org/2001/XMLSchema#string